Real world evidence on 5661 patients treated for macular oedema secondary to branch retinal vein occlusion with intravitreal anti-vascular endothelial growth factor, intravitreal dexamethasone or macular laser

Macular DiseasesRetinal DiseasesFurther Publications

Intraocular Pressure-Related Events After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical Trial

JAMA Ophthalmol

Aref AA, Scott IU, VanVeldhuisen PC, King J, Ip MS, Blodi BA, Oden NL, Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Investigator Group.

doi: 10.1001/jamaophthalmol.2021.4395

Retinal Diseases

Association of Disorganization of Retinal Inner Layers With Visual Acuity Response to Anti–Vascular Endothelial Growth Factor Therapy for Macular Edema Secondary to Retinal Vein Occlusion

JAMA Ophthalmol.

Babiuch AS, Han M, Conti FF, Wai K, Silva FQ, Singh RP

doi: 10.1001/jamaophthalmol.

COMMENTED

Retinal Diseases

Multicentre study of 4626 patients assesses the effectiveness, safety and burden of two categories of treatments for central retinal vein occlusion: intravitreal anti-vascular endothelial growth factor injections and intravitreal Ozurdex injections

★ 2 Recommended and commented by Dr habil. Gábor Márk Somfai, PhD, Faculty Member

Br J Ophthalmol

Gale R, Gill C, Pikoula M, Lee AY, Hanson RLW, Denaxas S, Egan C, Tufail A, Taylor P, UK EMR Database Users Group.

doi: 10.1136/bjophthalmol-2020-317306

Macular DiseasesRetinal Diseases

Risk factors of recurrence of macular oedema associated with branch retinal vein occlusion after intravitreal bevacizumab injection

Br J Ophthalmol.

Yoo JH, Ahn J, Oh J, Cha J, Kim SW

doi: 10.1136/

Macular DiseasesRetinal Diseases

Month 24 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: SCORE2 Report 10: A Secondary Analysis of the SCORE2 Randomized Clinical Trial

JAMA Ophthalmol.

Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA, Chan CK, SCORE2 Investigator Group.

doi: 10.1001/jamaophthalmol.

Macular Diseases

A systematic review of real-world evidence of the management of macular oedem secondary to branch retinal vein occlusion

Eye (Lond).

Ang JL, Ah-Moye S, Kim LN, Nguyen V, Hunt A, Barthelmes D, Gillies MC, Mehta H

doi: 10.1038/s41433-020-0861-9.

COMMENTED

Macular DiseasesRetinal Diseases

IMPACT OF LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ON PREEXISTING MICROSTRUCTURAL ALTERATIONS IN DIABETIC MACULAR EDEMA

Retina.

Wirth MA, Wons J, Freiberg FJ, Becker MD, Michels S

doi: 10.1097/IAE.

COMMENTED

Macular DiseasesRetinal Diseases

INCIDENCE AND LONG-TERM VISUAL ACUITY OUTCOMES OF RETINAL PIGMENT EPITHELIUM TEARS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Retina.

Vazquez-Alfageme C, Nicholson L, Hamilton RD, Patel PJ

doi: 10.1097/IAE.

COMMENTED

Macular Diseases

Association of Intravitreal Anti-Vascular Endothelial Growth Factor Therapy With Risk of Stroke, Myocardial Infarction, and Death in Patients With Exudative Age-Related Macular Degeneration

JAMA Ophthalmol.

Dalvin LA, Starr MR, AbouChehade JE, Damento GM, Garcia M, Shah SM, Hodge DO, Meissner I, Bakri SJ, Iezzi R

doi: 10.1001/jamaophthalmol.

Related content

Intraocular Pressure-Related Events After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical Trial

Association of Disorganization of Retinal Inner Layers With Visual Acuity Response to Anti–Vascular Endothelial Growth Factor Therapy for Macular Edema Secondary to Retinal Vein Occlusion

Multicentre study of 4626 patients assesses the effectiveness, safety and burden of two categories of treatments for central retinal vein occlusion: intravitreal anti-vascular endothelial growth factor injections and intravitreal Ozurdex injections

Risk factors of recurrence of macular oedema associated with branch retinal vein occlusion after intravitreal bevacizumab injection

Month 24 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: SCORE2 Report 10: A Secondary Analysis of the SCORE2 Randomized Clinical Trial

A systematic review of real-world evidence of the management of macular oedem secondary to branch retinal vein occlusion

IMPACT OF LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ON PREEXISTING MICROSTRUCTURAL ALTERATIONS IN DIABETIC MACULAR EDEMA

INCIDENCE AND LONG-TERM VISUAL ACUITY OUTCOMES OF RETINAL PIGMENT EPITHELIUM TEARS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Association of Intravitreal Anti-Vascular Endothelial Growth Factor Therapy With Risk of Stroke, Myocardial Infarction, and Death in Patients With Exudative Age-Related Macular Degeneration